As a consequence of the relatively high expression of CD47 on RBCs and platelets, hematotoxicity—which includes anemia, thrombocytopenia, hemagglutination, and neutropenia—has been a major concern among the various side effects observed in clinical studies of anti-CD47 therapies [16–18]. The gene discussed is CD47; the disease is anemia (phenotype).